AIF1 and glaucoma: IBA1 immunostaining was significantly reduced in WT NS (p < 0.0001) treated mice compared with NS−/− mice in glaucoma, but a greater decrease in IBA immunoreactivity was observed with M363R-NS treatment compared with WT NS treatment (p < 0.0005) (Figures S48C and S48D).